|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
|
US5697901A
(en)
|
1989-12-14 |
1997-12-16 |
Elof Eriksson |
Gene delivery by microneedle injection
|
|
FI101678B1
(fi)
|
1990-12-31 |
1998-08-14 |
Akzo Nv |
Happolabiileja kytkentämolekyylejä
|
|
US6613332B1
(en)
|
1991-06-21 |
2003-09-02 |
The University Of Cincinnati |
Oral administration of therapeutic proteins
|
|
WO1993000077A1
(en)
|
1991-06-21 |
1993-01-07 |
University Of Cincinnati |
Orally administrable therapeutic proteins and method of making
|
|
IL99120A0
(en)
|
1991-08-07 |
1992-07-15 |
Yeda Res & Dev |
Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
|
|
WO1993006217A1
(en)
|
1991-09-19 |
1993-04-01 |
Genentech, Inc. |
EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
|
|
US5505931A
(en)
|
1993-03-04 |
1996-04-09 |
The Dow Chemical Company |
Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
JPH11510050A
(ja)
|
1995-07-25 |
1999-09-07 |
イントロヘーネ ベスローテン フェンノートシャップ |
標的遺伝子送達のための方法および手段
|
|
WO1997029701A1
(en)
|
1996-02-15 |
1997-08-21 |
Biosense Inc. |
Catheter based surgery
|
|
EP0920339A2
(en)
|
1996-07-09 |
1999-06-09 |
The Johns Hopkins University |
Gene delivery system
|
|
US6541615B1
(en)
|
1996-11-15 |
2003-04-01 |
Max-Planck-Gellschaft Zur Foderung Der Wissenschaften E.V. |
SIRP proteins and uses thereof
|
|
CA2226962A1
(en)
|
1998-02-16 |
1999-08-16 |
Marie Sarfati |
Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
|
|
JP2003502062A
(ja)
|
1999-06-11 |
2003-01-21 |
ヒューマン ジノーム サイエンシーズ， インコーポレイテッド |
４９個のヒト分泌タンパク質
|
|
US6613026B1
(en)
|
1999-12-08 |
2003-09-02 |
Scimed Life Systems, Inc. |
Lateral needle-less injection apparatus and method
|
|
GB9930706D0
(en)
|
1999-12-24 |
2000-02-16 |
Medical Res Council |
Composition for inhibiting macrophage activity
|
|
US7662367B2
(en)
|
2000-03-02 |
2010-02-16 |
Xencor, Inc. |
Pharmaceutical compositions for the treatment of TNF-α related disorders
|
|
TWI334439B
(en)
|
2001-08-01 |
2010-12-11 |
Centocor Inc |
Anti-tnf antibodies, compositions, methods and uses
|
|
GB0124145D0
(en)
|
2001-10-08 |
2001-11-28 |
Bayer Ag |
Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
|
|
US20040018522A1
(en)
|
2002-05-09 |
2004-01-29 |
Brigham And Women's Hospital, Inc. |
Identification of dysregulated genes in patients with multiple sclerosis
|
|
WO2004011618A2
(en)
|
2002-07-29 |
2004-02-05 |
Hmgene, Inc. |
Methods of identifying adipocyte specific genes, the genes identified, and their uses
|
|
WO2004024097A2
(en)
|
2002-09-16 |
2004-03-25 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
CA2505316C
(en)
|
2002-11-08 |
2014-08-05 |
Ablynx N.V. |
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
|
|
US20100215640A1
(en)
|
2003-04-24 |
2010-08-26 |
The University Of North Carolina At Chapel Hill |
Method for inhibiting cellular activation by insulin-like growth factor-1
|
|
US20040213792A1
(en)
|
2003-04-24 |
2004-10-28 |
Clemmons David R. |
Method for inhibiting cellular activation by insulin-like growth factor-1
|
|
US8613922B2
(en)
|
2003-04-24 |
2013-12-24 |
The University Of North Carolina At Chapel Hill |
Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
|
|
US7691970B2
(en)
|
2003-08-25 |
2010-04-06 |
Pieris Ag |
Muteins of a bilin-binding protein with affinity for a given target
|
|
MXPA06009805A
(es)
|
2004-02-27 |
2007-04-02 |
Vaxconsulting |
Peptidos de interleucina 1 beta y factor de necrosis tumoral alfa y metodo de tratamiento utilizando los mismos.
|
|
EP1737480A2
(de)
|
2004-03-29 |
2007-01-03 |
Seth Hallström |
Pharmazeutisches kombinationspr parat enthaltend ein therape utisches protein
|
|
WO2005108415A2
(en)
|
2004-04-30 |
2005-11-17 |
Biogen Idec Ma Inc. |
Membrane associated molecules
|
|
US7514229B2
(en)
|
2005-09-29 |
2009-04-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for diagnosing and evaluating treatment of blood disorders
|
|
AR060017A1
(es)
|
2006-01-13 |
2008-05-21 |
Novartis Ag |
Composiciones y metodos de uso para anticuerpos de dickkopf -1
|
|
US8377448B2
(en)
|
2006-05-15 |
2013-02-19 |
The Board Of Trustees Of The Leland Standford Junior University |
CD47 related compositions and methods for treating immunological diseases and disorders
|
|
EP2144930A1
(en)
|
2007-04-18 |
2010-01-20 |
ZymoGenetics, Inc. |
Single chain fc, methods of making and methods of treatment
|
|
BRPI0810561A2
(pt)
|
2007-04-23 |
2019-09-24 |
Wyeth Corp |
métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13.
|
|
CA2697032C
(en)
|
2007-08-22 |
2021-09-14 |
The Regents Of The University Of California |
Activatable binding polypeptides and methods of identification and use thereof
|
|
US20100239578A1
(en)
|
2007-10-11 |
2010-09-23 |
University Health Network |
Modulation of sirp-alpha - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
|
|
ES2563027T3
(es)
|
2008-01-07 |
2016-03-10 |
Amgen Inc. |
Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
|
|
AU2009205665B2
(en)
|
2008-01-15 |
2013-12-05 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for manipulating phagocytosis mediated by CD47
|
|
EP2111869A1
(en)
|
2008-04-23 |
2009-10-28 |
Stichting Sanquin Bloedvoorziening |
Compositions and methods to enhance the immune system
|
|
US20110237498A1
(en)
|
2008-12-19 |
2011-09-29 |
Novartis Ag |
Soluble polypeptides for use in treating autoimmune and inflammatory disorders
|
|
US20100189651A1
(en)
|
2009-01-12 |
2010-07-29 |
Cytomx Therapeutics, Llc |
Modified antibody compositions, methods of making and using thereof
|
|
JP5861223B2
(ja)
|
2009-02-23 |
2016-02-16 |
サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. |
プロタンパク質およびその使用方法
|
|
PL2995315T3
(pl)
|
2009-05-15 |
2024-04-22 |
University Health Network |
Kompozycje i sposoby leczenia nowotworów hematologicznych celujące w oddziaływanie sirp alfa-cd47
|
|
US20110015130A1
(en)
|
2009-07-20 |
2011-01-20 |
Woei-Jer Chuang |
Polypeptides Selective for alphavbeta3 Integrin Conjugated With a Variant Of Human Serum Albumin (HSA) And Pharmaceutical Uses Thereof
|
|
KR101632312B1
(ko)
|
2009-11-03 |
2016-06-21 |
삼성전자주식회사 |
항체 불변 영역에 특이적으로 결합하는 융합 단백질, 그의 제조 방법 및 이를 이용한 항체 분리 방법
|
|
ES2751549T3
(es)
|
2009-11-30 |
2020-04-01 |
Janssen Biotech Inc |
Mutantes de anticuerpos Fc con funciones efectoras ablacionadas
|
|
AU2010334974A1
(en)
|
2009-12-22 |
2012-07-12 |
Novartis Ag |
Tetravalent CD47-antibody constant region fusion protein for use in therapy
|
|
HRP20221260T1
(hr)
|
2010-05-14 |
2023-03-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Humanizirana i kimerna monoklonska protutijela za cd47
|
|
CN103501815B
(zh)
|
2010-10-08 |
2016-09-28 |
希望之城公司 |
针对中间位的单克隆抗体框架结合界面、中间位投递系统及其使用方法
|
|
US8609621B2
(en)
|
2010-11-15 |
2013-12-17 |
E I Du Pont De Nemours And Company |
Acid-cleavable linkers exhibiting altered rates of acid hydrolysis
|
|
WO2012109267A2
(en)
|
2011-02-07 |
2012-08-16 |
The Trustees Of The University Of Pennsylvania |
Novel peptides and methods using same
|
|
SG10201602394QA
(en)
|
2011-03-29 |
2016-05-30 |
Roche Glycart Ag |
Antibody FC Variants
|
|
RS55609B1
(sr)
|
2011-04-13 |
2017-06-30 |
Bristol Myers Squibb Co |
Fc fuzioni proteini koji sadrže nove linkere ili aranžmane
|
|
UA118950C2
(uk)
|
2011-04-22 |
2019-04-10 |
Аптево Рісьорч Енд Девелопмент Ллс |
Поліпептид, який зв'язує специфічний мембранний антиген простати та комплекс т-клітинного рецептора
|
|
MX2013014789A
(es)
|
2011-06-16 |
2014-01-20 |
Novartis Ag |
Proteinas solubles para utilizarse como productos terapeuticos.
|
|
WO2013056352A1
(en)
|
2011-10-19 |
2013-04-25 |
University Health Network |
Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
|
|
WO2013063076A1
(en)
|
2011-10-25 |
2013-05-02 |
Indiana University Research & Technology Corporation |
Compositions for and methods of modulating complications, risks and issues with xenotransplantation
|
|
SI2804617T1
(sl)
|
2012-01-17 |
2020-10-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Visokoafinitetni SIRP-alfa reagenti
|
|
US9428553B2
(en)
|
2012-02-10 |
2016-08-30 |
City Of Hope |
Meditopes and meditope-binding antibodies and uses thereof
|
|
WO2013192546A1
(en)
|
2012-06-22 |
2013-12-27 |
Cytomx Therapeutics, Inc. |
Activatable antibodies having non-binding steric moieties and mehtods of using the same
|
|
MX2014016038A
(es)
|
2012-06-22 |
2015-08-14 |
Cytomx Therapeutics Inc |
Anticuerpos de reaccion cruzada anti - jagged 1 / jagged 2, anticuerpos anti - jagged activables y metodos para uso de los mismos.
|
|
GB201216649D0
(en)
|
2012-09-18 |
2012-10-31 |
Univ Birmingham |
Agents and methods
|
|
ES2914814T3
(es)
|
2012-12-17 |
2022-06-16 |
Pf Argentum Ip Holdings Llc |
Tratamiento de células enfermas CD47+ con fusiones SIRP Alfa-Fc
|
|
US9873747B2
(en)
|
2013-01-31 |
2018-01-23 |
Thomas Jefferson University |
Fusion proteins that facilitate cancer cell destruction
|
|
CA2900256C
(en)
|
2013-02-05 |
2023-03-21 |
Kim J. HASENKRUG |
Cd47 targeted therapies for the treatment of infectious disease
|
|
WO2014160183A1
(en)
|
2013-03-13 |
2014-10-02 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Methods for modulating chemotherapeutic cytotoxicity
|
|
PT2970493T
(pt)
|
2013-03-15 |
2019-06-27 |
Univ Leland Stanford Junior |
Métodos para obter doses terapeuticamente eficazes de agentes anti-cd47
|
|
ES2898627T3
(es)
|
2013-04-29 |
2022-03-08 |
Univ Leland Stanford Junior |
Uso de agentes anti-CD47 para mejorar la inmunización
|
|
WO2014186761A2
(en)
|
2013-05-17 |
2014-11-20 |
The Board Of Trustes Of The Leland Stanford Junior University |
Methods for determining responsiveness to an anti-cd47 agent
|
|
SG11201600734YA
(en)
|
2013-07-31 |
2016-02-26 |
Amgen Inc |
Stabilization of fc-containing polypeptides
|
|
ES2765483T3
(es)
|
2013-09-18 |
2020-06-09 |
Univ Leland Stanford Junior |
Modulación de las vías de eferocitosis para el tratamiento de una enfermedad aterosclerótica
|
|
CN105592695B
(zh)
|
2013-09-23 |
2018-04-10 |
瑞泽恩制药公司 |
具有人源化信号调节蛋白基因的非人动物
|
|
CA2925106C
(en)
|
2013-09-25 |
2023-11-14 |
Cytomx Therapeutics, Inc. |
Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
|
|
KR102339240B1
(ko)
|
2013-10-15 |
2021-12-15 |
더 스크립스 리서치 인스티튜트 |
펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도
|
|
IL270562B
(en)
|
2014-01-31 |
2022-08-01 |
Cytomx Therapeutics Inc |
Polypeptide substrates that activate matriptase and u-plasminogen and other cleavable groups, preparations containing them and their uses
|
|
US10519237B2
(en)
|
2014-03-12 |
2019-12-31 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
|
US9394365B1
(en)
|
2014-03-12 |
2016-07-19 |
Yeda Research And Development Co., Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
|
|
AU2015228372B2
(en)
|
2014-03-12 |
2018-05-31 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
|
US10087257B2
(en)
|
2014-08-08 |
2018-10-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
SIRP alpha-antibody fusion proteins
|
|
TWI759810B
(zh)
|
2014-08-08 |
2022-04-01 |
美商Ａｌｘ腫瘤技術股份有限公司 |
信號調節蛋白α(signal-regulatory proteinα, SIRP-α)變體構築物及其用途
|
|
US9546206B2
(en)
|
2014-08-08 |
2017-01-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
High affinity PD-1 agents and methods of use
|
|
WO2016023001A1
(en)
|
2014-08-08 |
2016-02-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Multispecific high affinity pd-1 agents and methods of use
|
|
HUE046661T2
(hu)
|
2014-08-15 |
2020-03-30 |
Merck Patent Gmbh |
SIRP-alfa immunglobulin fúziós proteinek
|
|
FI3656869T4
(fi)
|
2014-08-26 |
2025-06-04 |
Univ Leland Stanford Junior |
Kantasolujen siirrostaminen kantasoluihin kohdentuvan aineen ja immunoregulatorista signaalia moduloivan aineen yhdistelmän kanssa
|
|
EP3194024B1
(en)
|
2014-09-15 |
2020-08-05 |
The Board of Trustees of the Leland Stanford Junior University |
Targeting aneurysm disease by modulating phagocytosis pathways
|
|
WO2016057980A1
(en)
|
2014-10-10 |
2016-04-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods to eliminate cancer stem cells by targeting cd47
|
|
EP3209769B1
(en)
|
2014-10-24 |
2020-08-05 |
The Board of Trustees of the Leland Stanford Junior University |
Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
|
|
EP3012271A1
(en)
|
2014-10-24 |
2016-04-27 |
Effimune |
Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
|
|
PT3212670T
(pt)
*
|
2014-10-29 |
2021-02-15 |
Bristol Myers Squibb Co |
Terapêutica de combinação para cancro
|
|
CA2967379A1
(en)
|
2014-11-18 |
2016-05-26 |
Janssen Pharmaceutica Nv |
Cd47 antibodies, methods, and uses
|
|
US11253588B2
(en)
|
2015-02-27 |
2022-02-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Combination therapy for treatment of coronary artery disease
|
|
CN106146670B
(zh)
|
2015-04-24 |
2019-01-15 |
宜明昂科生物医药技术（上海）有限公司 |
一种新的重组双功能融合蛋白及其制备和应用
|
|
WO2017027422A1
(en)
|
2015-08-07 |
2017-02-16 |
Alexo Therapeutics Inc. |
Constructs having a sirp-alpha domain or variant thereof
|
|
US10613092B2
(en)
*
|
2016-04-01 |
2020-04-07 |
Agilent Technologies, Inc. |
Scoring methods for anti-PD therapy eligibility and compositions for performing same
|
|
SG11201808465UA
(en)
|
2016-04-14 |
2018-10-30 |
Ose Immunotherapeutics |
NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
|
|
FR3053561A1
(fr)
|
2016-06-29 |
2018-01-05 |
Orange |
Controle de connexion a un reseau local installe a bord d'un vehicule
|
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
|
AU2017339517B2
(en)
*
|
2016-10-06 |
2024-03-14 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
PT3565844T
(pt)
*
|
2017-01-09 |
2023-05-02 |
Tesaro Inc |
Métodos de tratamento de cancro com anticorpos anti-pd-1
|
|
JP2020515637A
(ja)
*
|
2017-04-03 |
2020-05-28 |
オンコロジー、インコーポレイテッド |
免疫腫瘍剤を伴うｐｓ標的化抗体を用いる癌の治療方法
|
|
AU2019218271B2
(en)
*
|
2018-02-12 |
2024-12-12 |
Forty Seven, LLC |
Anti-cancer regimen using anti-CD47 and anti-CD20 antibodies
|
|
BR112021024003A2
(pt)
|
2019-05-31 |
2022-04-19 |
Alx Oncology Inc |
Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico
|
|
CN114206912B
(zh)
|
2019-06-07 |
2025-02-11 |
Alx肿瘤生物技术公司 |
用于在血清学测定中减少结合cd47的药物的干扰的方法和试剂
|
|
AU2020394204A1
(en)
|
2019-11-27 |
2022-06-02 |
ALX Oncology Inc. |
Combination therapies for treating cancer
|
|
US12343377B2
(en)
*
|
2020-06-01 |
2025-07-01 |
ALX Oncology Inc. |
Combination therapies comprising a hypomethylation agent for treating cancer
|
|
WO2022010806A1
(en)
|
2020-07-06 |
2022-01-13 |
ALX Oncology Inc. |
Methods for reducing the interference of drugs that bind therapeutic targets expressed on blood cells in serological assays
|
|
WO2022120286A1
(en)
|
2020-12-06 |
2022-06-09 |
ALX Oncology Inc. |
Multimers for reducing the interference of drugs that bind cd47 in serological assays
|
|
JP2024520902A
(ja)
*
|
2021-05-13 |
2024-05-27 |
エーエルエックス オンコロジー インコーポレイテッド |
がんを治療するための併用療法
|